Management of Ovarian Hyperstimulation Syndrome
For routine assisted reproductive therapy, do not use thromboprophylaxis; however, if severe ovarian hyperstimulation syndrome develops, immediately initiate prophylactic-dose LMWH (enoxaparin 40 mg daily) for 3 months post-resolution to prevent life-threatening thromboembolism. 1
Risk Stratification and Prevention Strategy
For Standard ART Patients (No OHSS)
- Avoid routine anticoagulation - the baseline VTE risk is only 0.2% (2 per 1,000), making prophylaxis unnecessary with a number needed to treat of 781 1, 2
- The evidence strongly supports withholding prophylaxis in uncomplicated cases (Grade 1B recommendation) 1
For Severe OHSS (Critical Decision Point)
When severe OHSS develops—characterized by capillary leak syndrome with pleural effusion, ascites, and potential arterial/venous thrombosis—the VTE risk jumps dramatically to 4% (40 per 1,000) 1. This 20-fold increase in thrombotic risk demands immediate action.
Initiate LMWH prophylaxis:
- Enoxaparin 40 mg subcutaneously daily (prophylactic dose) 3
- Start immediately upon OHSS diagnosis
- Continue for 3 months post-resolution of clinical OHSS 1
- This reduces VTE by 26 per 1,000 treated (NNT = 39) without increasing major bleeding risk 1
Special Populations Requiring Different Approach
Antiphospholipid Antibody-Positive Patients
These patients face compounded thrombotic risk from both elevated estrogen during stimulation and underlying thrombophilia 3.
Management algorithm:
- Asymptomatic aPL-positive: Prophylactic LMWH (enoxaparin 40 mg daily) starting at ovarian stimulation initiation 3
- Obstetric APS: Prophylactic LMWH (strong recommendation) 3
- Thrombotic APS: Therapeutic-dose LMWH (enoxaparin 1 mg/kg subcutaneously every 12 hours) 3
Timing specifics:
- Withhold LMWH 24-36 hours before oocyte retrieval 3
- Resume immediately after retrieval 3
- Continue until estrogen normalizes (if no pregnancy) or throughout pregnancy (if conception occurs) 3
- Avoid aspirin before retrieval due to bleeding risk at retrieval; start post-retrieval if indicated 3
Critical Caveat
Two of four reported thromboses in aPL-positive patients occurred when women self-discontinued LMWH after oocyte retrieval 3—emphasizing the importance of patient education about continuation.
Additional Prevention Measures
Beyond anticoagulation, patients at high OHSS risk benefit from:
- Ovarian stimulation protocols using aromatase inhibitors to achieve lower peak estrogen levels 3
- GnRH antagonist protocols (preferred over agonist protocols for OHSS prevention) 4, 5
- GnRH agonist trigger instead of hCG trigger in antagonist cycles 4, 5
- Dopamine agonists (cabergoline 0.5 mg daily) 6, 4
Management of Established OHSS
Outpatient management (moderate cases):
- Maintain adequate hydration
- Prophylactic LMWH as above
- Never use diuretics (worsens intravascular depletion) 6
Inpatient management (severe/critical cases):
- Hospitalization for fluid balance monitoring
- Paracentesis for symptomatic ascites (can reinfuse drained fluid to maintain intravascular volume) 6, 7
- Therapeutic anticoagulation if thrombosis develops
- Multidisciplinary care for critical cases 7
Evidence Quality Note
The 2012 ACCP guidelines 1 provide the most comprehensive thromboprophylaxis recommendations (Grade 1B against routine prophylaxis, Grade 2C for OHSS prophylaxis), while the 2020 ACR guidelines 3 offer the most recent guidance for aPL-positive patients. The evidence quality is rated as low due to indirectness (extrapolated from hip arthroplasty data) and imprecision in VTE risk estimates, but the magnitude of benefit in severe OHSS (26 fewer VTE per 1,000) with no increased bleeding risk supports the recommendation 1.